

Analyzing Host-Viral Interactome of SARS-CoV-2 for Identifying Vulnerable Host Proteins during COVID-19 Pathogenesis

Jayanta Kumar Das^a, Swarup Roy^{b,*}, Pietro Hiram Guzzi^{c,*},

^aDepartment of Pediatrics, Johns Hopkins University School of Medicine, Maryland, USA

^bNetwork Reconstruction & Analysis (NetRA) Lab, Department of Computer Applications, Sikkim University, Gangtok, India

^cDepartment of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy

Abstract

The development of therapeutic targets for COVID-19 treatment is based on the understanding of the molecular mechanism of pathogenesis. The identification of genes and proteins involved in the infection mechanism is the key to shed out light into the complex molecular mechanisms. The combined effort of many laboratories distributed throughout the world has produced the accumulation of both protein and genetic interactions. In this work we integrate these available results and we obtain an host protein-protein interaction network composed by 1432 human proteins. We calculate network centrality measures to identify key proteins. Then we perform functional enrichment of central proteins. We observed that the identified proteins are mostly associated with several crucial pathways, including cellular process, signalling transduction, neurodegenerative disease. Finally, we focused on proteins involved in causing disease in the human respiratory tract. We conclude that COVID-19 is a complex disease, and we highlighted many potential therapeutic targets including RBX1, HSPA5, ITCH, RAB7A, RAB5A, RAB8A, PSMC5, CAPZB, CANX, IGF2R, HSPA1A, which are central and also associated with multiple diseases.

Keywords: SARS-CoV-2, COVID-19, Protein-protein interaction, Centrality, Pathways, Disease

1. Introduction

The world is experiencing an unprecedented pandemic due to a massive outbreak of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infected viral disease, COVID-19. SARS-CoV-2, is a large enveloped coronavirus (family-*Coronaviridae*, subfamily-*Coronavirinae*) with non-segmented, single-stranded, and positive-sense RNA genomes [1], transmits rapidly through human to human contacts. Although SARS-CoV-2 is similar to other known coronaviruses, i.e. SARS-CoV and MERS-CoV [2, 3], it has demonstrated high rates of infection [4, 5]. Therefore there is the need to understand the disease pathogenesis of SAR-CoV-2 to develop effective therapies and vaccines.

The SARS-CoV-2 virus is responsible COVID-19 disease that causes damages in multiple organs as the disease progresses from an asymptomatic phase to a life-threatening disease [6]. Therefore, accurate molecular diagnosis of COVID-19 disease is essential by collecting the proper respiratory tract specimen [7]. In this context, the integrated analysis [8] of various data-sets, including clinical and imaging data, may explain, and hopefully predict, the longitudinal effects of SARS-CoV-2 infection [9, 10]. In particular, many independent projects throughout the world have focused on genomics and proteomics level [10], and then they integrated these data with clinical ones. These works have produced data about the infection's effect at a molecular scale, evidencing genes and proteins' role, such as the interactions among viral and human proteins. Interactions between a host and its pathogen, are primarily driven by interactions among the host proteins and pathogen proteins; also referred to as host-pathogen protein-protein interaction (PPI) network. The SARS-CoV-2 virus-host interactome have been studied focusing various virulence factors influencing SARS-CoV-2 pathogenesis and interacting mechanism [11, 12, 13, 14, 15, 16]. Further, many recent works also used host-viral protein-protein interaction network as an input to elucidate potential drug targets or repurposed drug molecules [17, 18, 19]. Host-pathogen protein interactions provide important insights into the molecular mechanisms of pathogenicity [20] and for understanding virulence factors influencing SARS-CoV-2 pathogenesis [21, 22]. SARS-CoV-2 is a newly found virus whose interacting human host proteins play a major disease progression role that needs to be investigated.

*Corresponding Author

Email addresses: jdas4@jhmi.edu (Jayanta Kumar Das), sroy01@cus.ac.in (Swarup Roy), sroy01@cus.ac.in (Pietro Hiram Guzzi)

Protein-Protein Interactions (PPI) are usually modelled and analysed with graph theory [23]. In this formalism, the interactions are modelled as a graph whose nodes are proteins (or genes), and the edges are the interaction among them. Several studies have found that specific candidate proteins might play a crucial role [24, 25, 26, 27]. Protein-protein interaction networks are an essential ingredient for any systems-level understanding of cellular processes and modelling, and even drug discovery [28, 29, 30, 31, 32]. The key genes/proteins involved in the different biological pathways can give valuable insight for in-depth characterisation of disease progression [33, 34, 35]. It is well accepted that all the viruses have evolved to target proteins that are central and have strong control over the human interactome [36, 37, 38, 39, 40]. Exploring the predicted interaction networks can suggest new directions for future experimental research and provide cross-species predictions for efficient interaction mapping [41, 34]. The complete workflow of the current study can be seen from Figure 1.




Figure 1: The complete work-flow of the current study.

This study aims to identify essential human host proteins based on topology analysis of the protein-protein interaction network of SARS-CoV-2 interacting human host proteins. We performed functional enrichment of the identified proteins to shed out light on cellular, signalling, and disease pathways.

2. Materials and Method

2.1. Dataset: Curated SARS-CoV-2 interacting human host proteins

We use recently reported host proteins that are physically verified using Affinity purification mass spectrometry for their interactions with SARS-CoV-2 [17, 21, 42]. The used host-viral protein interactions are also available in BioGRID [43]. A total of 2489 host-viral interactions (consisting of 1432 unique host proteins interacting with 37 SARS-CoV-2 viral proteins) are obtained. In Figure 2, we provided the number of interacting host protein count. It is noted that the majority of the host proteins are targeted to the specific viral protein.

2.2. Construction of Host PPI network

Starting with the human proteins that are interacting with the virus, we build a host PPI by querying the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, Version 10.0; <http://string-db.org/>) [44].

The topology analysis of the PPI network is performed by using Cytoscape (<http://apps.cytoscape.org/>), a general platform for complex network analysis and visualization [45].

2.3. Centrality analysis of host PPI network

In network analysis, indicators of centrality identify the most critical nodes in the network [46]. The centrality measure uses to characterise each node and edge in the PPI network. The degree measure is the most intuitive for topology analysis of the PPI network. Several other crucial factors that can influence network links are betweenness centrality, closeness centrality, clustering coefficient, topological coefficient, and neighbourhood connectivity.




Figure 2: The abundance (percentage) of collected interacting human host protein for different SARS-CoV-2 viral proteins. A host-viral interaction network pattern is also shown.

- (i) **Degree centrality:** The degree centrality (simply degree) of a node n in a network is defined as (D_n) , which indicates number of directly connected nodes to n . The densely connected nodes in PPI network is considered hub nodes [47].
- (ii) **Betweenness centrality:** Betweenness centrality quantifies the number of times a node acts as a bridge along the shortest path between two other nodes [48]. The betweenness centrality of a node n is represented as:

$$C_b(n) = \sum_{s \neq n \neq t} (\sigma_{st}(n) / \sigma_{st}) \quad (1)$$

where σ_{st} is the total number of shortest paths from node s to node t and $\sigma_{st}(n)$ is the number of those paths that pass through n .

- (iii) **Closeness centrality:** Closeness centrality is a way of detecting nodes that are able to spread information very efficiently through the network [49]. It can be calculated as :

$$C_c(n) = 1 / \text{avg}(L(m, n)) \quad (2)$$

where $L(m, n)$ is the length of shortest path between node n and m , and m denotes any other nodes that are reachable to node n .

- (iv) **Average shortest-path length:** Shortest-path length between two nodes (say n and m) in network topology is defined as the number of minimum steps that required to traverse between node n and m ! [50]. The average shortest path length (S_p) of node n is the average value of all pair of nodes shortest path from the node n .
- (v) **Clustering coefficient:** Clustering coefficient is a measure of the degree to which nodes in a graph tend to cluster together [51]. In undirected networks, the clustering coefficient C_n of a node n is defined as:

$$C_n = 2e_n / (k_n(k_n - 1)) \quad (3)$$

where k_n is the number of neighbors of n and e_n is the number of connected pairs between all neighbors of n .

- (vi) **Topological coefficient:** Topological coefficient is a relative measure for the extent to which a node shares neighbors with other nodes [52]. The topological coefficient T_n of a node n with k_n neighbors is computed as follows:

$$T_n = \text{avg}(J(n, m)) / k_n \quad (4)$$

Where $J(n, m)$ is defined for all nodes m that share at least one neighbour with n , and the value $J(n, m)$ is the number of neighbours shared between the nodes n and m , plus one if there is a direct link between n and m .

(vii) **Neighborhood connectivity:** Neighborhood connectivity (N_c) of a node n is defined as the average connectivity of all neighbors of n [53]. The neighborhood connectivity distribution gives the average of the neighborhood connectivities of all nodes n with k neighbors for $k = 0, 1, \dots$.

We used NetworkAnalyzer [45] to calculate above centrality score. In NetworkAnalyzer, C_c (Closeness centrality) is calculated as the reciprocal of the average shortest path length. So, high C_c means highly central, and thus low S_p .

2.4. Gene ontology and pathway enrichment analysis

We performed enrichment analysis to find out set of significantly enriched genes/proteins in different functional and biological pathways. We used KEGG (Kyoto Encyclopedia of Genes and Genomes) [54] for elucidating pathway enrichment of a host protein and Gene Ontology (GO) for the assessment of protein functions [55]. KEGG is a database resource for understanding high-level functions and utilities of the biological system [56].

2.5. Gene-disease association network

Complex diseases are caused by a group of genes known as disease genes. More often, a gene can participate in various disease conditions [57, 58]. It helps unravel the disease pathogenesis, which in turn help disease diagnosis, treatment, and disease prevention. We obtained gene-disease association network from DisGeNET (v7.0) database (<https://www.disgenet.org/>), which contains 1,134,942 gene-disease associations (GDAs), between 21,671 genes and 30,170 disease [59]. From this database, we considered curated gene-disease associations only.

3. Results and Discussion

Here, we report the outcomes of intermediate steps to reach to our objective of isolating key host proteins followed by their significance analysis.

3.1. Deriving PPI network for candidate host proteins

Our candidate host proteins list, collected from the reported host-viral networks (Section 2), consists of total of 1432 distinct proteins that are targeted by SARS-CoV-2 during COVID-19. We rebuilt the PPI network centered around our candidate proteins using STRING DB. There are 7076 edges in the derived PPI network. We curated derived PPI by keeping only the interactions whose confidence scores are at least 0.7 (high confidence). The derived PPI network is then analysed using Cytoscape. We identified the big connected component (also called gain/main component) of the PPI network. After discarding all disconnected components in the PPI network, we considered gain component of PPI network with 1111 nodes (Approx. 78%) and 7043 edges (Figure 3).

3.2. Network topology analysis of gain component

We performed topological analysis of the gain component using NetworkAnalyzer [45]. The degree distribution of all the candidate proteins in the gain component showed that the majority of the proteins in the gain component exhibit a higher degree of connectivity (Figure 4). Few proteins with degree (shown within parentheses) more than 50 are *CDK1(73)*, *PPP2R1A(65)*, *NOP56(60)*, *POLR2B(60)*, *RAB1A(59)*, *RBX1(58)*, *SKIV2L2(57)*, *NAPA(57)*, *RPS14(56)*, *STX5(54)*, *TGOLN2(54)*, *TCEB1(53)*, *DCTN2(53)*, *TCEB2(52)*, *HSPA9(51)*, *GNB2L1(50)*.

The histogram analysis of all the centrality measures (discussed in section 2.3) showing non-random distribution (Figure S1). We performed correlation (Pearson) analysis among all centrality scores (Table 1). The correlation score between degree centrality (D_c) scores and closeness centrality (C_c) scores observed to be the highest ($r = 0.759$) in comparison to other measures. Although, we observed correlation between D_c and neighbourhood centrality (N_c) is the third-highest ($r = 0.557$), but N_c and B_c showed less correlative ($r = 0.1101$). Overall, we observed correlation score of three centrality measures (D_c, B_c, C_c) are quite closer. Therefore, we selected them in subsequent analysis. We identified 373 proteins in these criteria, which are considered highly central proteins (above the median score for all three selected parameters). When we considered all measures, we find only six common proteins (*GEMIN4*, *DDX20*, *GOLGA3*, *FKBP15*, *PMPCA*, *AK4*) above the median score in each category of centrality measurement, and that is the reason why we selected three centrality measures for our downstream analysis.




Figure 3: The gain component of PPI network consisting of 1111 nodes and 7043 edges obtained from whole PPI network.




Figure 4: The degree distribution of all 1111 nodes (proteins) in gain component of PPI network. The x-axis indicates degree distribution, whereas y-axis shows relative frequency distributions.

Table 1: Correlation analysis among all centrality parameters computed for 1111 proteins (Figure 3).

	D_c	B_c	C_{coef}	T_c	N_c
B_c	0.603	1			
C_{coef}	0.209	-0.168	1		
T_c	-0.32	-0.283	0.451	1	
N_c	0.557	0.1101	0.346	-0.139	1
C_c	0.759	0.5146	0.213	-0.329	0.684




Figure 5: The top 7 enriched pathways in each category of KEGG pathways. In each category, pathways are shown ordered by $-\log_{10}(p)$ value..

3.3. Pathway enrichment analysis of highly central proteins

We performed KEGG pathway analysis of selected 373 highly central proteins. We obtained a total of 84 enriched KEGG pathways within the significant level ($adj-p < .05$). The enriched pathways were involved in Cellular Processes (9), Environmental Information Processing (9), Genetic Information Processing (13), Human Disease (31), Organismal Systems (15), Metabolism (7). The top seven pathways in each category are shown in Figure 5.

Our current study mainly focused on the proteins that are involved in cellular process, signalling transduction, and human disease (viral and neurodegenerative) pathways, the most affected pathways in the context of COVID-19 disease [60, 61, 62, 63]. There are nine enriched pathways in **cellular process** (Endocytosis, Phagosome, Adherens junction, Tight junction, Cell cycle, Cellular senescence, Focal adhesion, Regulation of actin cytoskeleton, Lysosome), nine pathways in **Environmental Information Processing**-signalling transduction (Ras signalling pathway, HIF-1 signalling pathway, Hippo signalling pathway, Apelin signalling pathway, MAPK signalling pathway, TGF-beta signalling pathway, AMPK signalling pathway, NF-kappa B signalling pathway), nine pathways from **human disease viral** sub-category (Human immunodeficiency virus 1 infection, Human papillomavirus infection, Human cytomegalovirus infection, Hepatitis B, Human T-cell leukaemia virus 1 infection, Influenza A, Hepatitis C, Measles) and four pathways from **neurodegenerative disease** with sub-category (Huntington disease, Parkinson disease, Alzheimer disease, Prion diseases). A total of 141 distinct proteins (out of 373) were obtained from these pathways, which are then ranked based on presence in selected enriched pathways, and we found that 79 proteins are associated in our candidate pathways. All these proteins were then further studied for




Figure 6: The top 10 enriched terms in each category of gene ontology (BP-Biological process, MF-Molecular function, CC-Cellular component). In each category, terms are shown ordered by $\log_{10}(\text{combined score})$ value..

disease-gene association in the next.

We also performed gene set enrichment analysis (Gene ontology). It is observed that out of selected genes mostly involved in Biological process (*Supplementary-B*). The top ten terms in each category of gene ontology (BP, MF, CC) are shown in Figure 6 that includes neutrophil mediated immunity (GO:0002446), neutrophil activation involved in immune response (GO:0002283) and viral process (GO:0016032) from BP category; dolichyl-diphosphooligosaccharide-protein glycotransferase activity (GO:0004579), GDP binding (GO:0019003), cadherin binding (GO:0045296) and ATPase activity (GO:0016887) from MF category; and focal adhesion (GO:0005925) from CC category.




Figure 7: Comparison of three groups of disease categories (Cardiovascular, Respiratory, Immune system) using venn-diagram. (a) based on number protein count in each category; (b) based on number of disease associated (curated from database) among the observed protein in each category.

3.4. Analysis of Disease-gene associations

The identified 141 genes involved in four significant pathways (cellular process, signalling transduction, viral and neurodegenerative) are further screened by looking into their association with COVID-19 related disease. We particularly focused on three highly influential diseases during COVID-19, namely cardiovascular, respiratory tract [64, 65, 66, 67] and immune system disease [68, 69]. To obtain disease-gene association, we used DisGeNET database [59] and selected *CURETED* source only. We found a total of 64 proteins (out of 141) playing roles in various diseases such as *Asthma, Pneumonitis, Pneumonia, Influenza, Lung diseases, Cardiomyopathies, Coronary, Arteriosclerosis, Coronary Artery Disease, Heart failure, HIV Infections* etc. (Supplementary-C). We compared proteins involved in all three disease categories and individual disease in each category (Figure 7). A total of 119, 37, and 48 unique diseases, and 44, 17, and 24 distinct proteins are associated with the Cardiovascular, Respiratory, and Immune system disease category, respectively. Interestingly, we found a few proteins that are associated with all three disease categories (AREG, CAV1, IFIH1, PARP1, PLAU, TGFB1, ATM, B2M, DDX58, ENO1, HSPA5, PRKDC, STAT6, TGFBR1, TGFBR2). The top few proteins with ten or more disease associations are PLAU(59), TGFB1(29), CAV1(17), PARP1(17), TGFBR2(13), ATP2A2(11), AREG(10), FASN(10), IFIH1(10), ITGB1(10). The list of all 64 proteins and their associated quantitative parameters (degree, disease count (out of 204), disease type count (out of 3), and pathway count (out of 31) are presented in Table 2.

3.5. Viral proteins targeting key proteins

We then looked into source network (Figure 2) to identify the viral proteins that are targeting our selected 65 disease associated proteins. We found 25 SARS-CoV-2 proteins that are interacting with 65 proteins. Among 25 SARS-CoV-2 viral proteins, eight are accessory proteins (Orf3a, Orf7b, Orf6, Orf7a, Orf7b, Orf8, Orf9b, Orf10), four structural proteins (E,M,N,S) and thirteen non-structural poly-proteins (nsp1, nsp10, nsp12, nsp13, nsp14, nsp2, nsp3, nsp4, nsp5, nsp6, nsp7, nsp8, nsp9). It is observed that several host proteins are interacting with single viral protein. Very few host proteins are interacting with more than one viral proteins. The viral protein Orf7b exhibits the maximum number of target host proteins followed by Orf3a and M protein. Further, five host proteins are found to be common both in Orf3a and Orf7b.

We look further for any other viruses that are targeting our 65 host proteins. We mine VirusMINT [70], a virus-host association database, to find the other related viral diseases. We found that the majority of the highlighted host proteins are also targeted by *Hepatitis C virus genotype 1b, Poliovirus Type 1, Human herpesvirus 1, Human papillomavirus type 16 & 31, Simian virus 40, Sendai virus, Human adenovirus 5 & 12, Epstein-Barr virus, Human SARS coronavirus Bovine papillomavirus type 1, and Epstein-Barr virus* (Table 2). These proteins might be highly essential and need to put uttermost importance on developing host-directed antiviral therapies for COVID-19.

4. Conclusion

In this study, we have analysed human host protein-protein interaction network during the SARS-CoV-2 infection. We identified a set of proteins, including RBX1, HSPA5, ITC1, RAB7A, RAB5A, RAB8A, PSMC5, CAPZB, CANX, IGF2R, HSPA1A, which might influence the whole PPI network. These proteins were enriched for the following processes: cellular process, signalling, and neurodegenerative disease pathways as these pathways are known to be highly infectious for disease pathogenesis during COVID-19. Finally, we have found 64 potential/key SARS-CoV-2 interacting human host proteins connected with respiratory, cardiovascular, and immune system disease. Many of them are known to target different other viruses and may be highly important for therapeutics treatment of COVID-19 viral disease. We strongly believe that the highlighted key proteins are an extremely promising target, which might play a crucial role during COVID-19 disease progression.

References

- [1] D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-em structure of the 2019-ncov spike in the prefusion conformation, *Science* 367 (2020) 1260–1263.
- [2] S. Perlman, J. Netland, Coronaviruses post-sars: update on replication and pathogenesis, *Nature reviews microbiology* 7 (2009) 439–450.
- [3] R. J. de Groot, S. C. Baker, R. S. Baric, C. S. Brown, C. Drosten, L. Enjuanes, R. A. Fouchier, M. Galiano, A. E. Gorbalenya, Z. A. Memish, et al., Commentary: Middle east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group, *Journal of virology* 87 (2013) 7790–7792.




Figure 8: The interaction network represents the most influential host protein and viral protein. The network is consisting of sixty-four human proteins interacting with twenty-five SARS-CoV-2 viral proteins. The yellow colour represents the viral protein in the network, whereas the green one represents the host protein.

- [4] Y. Liu, A. A. Gayle, A. Wilder-Smith, J. Rocklöv, The reproductive number of covid-19 is higher compared to sars coronavirus, *Journal of travel medicine* (2020).
- [5] V. Surveillances, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (covid-19)—china, 2020, *China CDC Weekly* 2 (2020) 113–122.
- [6] K. Servick, For survivors of severe covid-19, beating the virus is just the beginning, *Science* (2020).
- [7] A. D. Whetton, G. W. Preston, S. Abubeker, N. Geifman, Proteomics and informatics for understanding phases and identifying biomarkers in covid-19 disease, *Journal of proteome research* 19 (2020) 4219–4232.
- [8] L. Antonelli, M. R. Guarracino, L. Maddalena, M. Sangiovanni, Integrating imaging and omics data: A review, *Biomedical Signal Processing and Control* 52 (2019) 264–280.
- [9] Y.-W. Tang, J. E. Schmitz, D. H. Persing, C. W. Stratton, Laboratory diagnosis of covid-19: current issues and challenges, *Journal of clinical microbiology* 58 (2020).
- [10] J. K. Das, G. Tradigo, P. Veltri, P. H. Guzzi, S. Roy, Data science in unveiling covid-19 pathogenesis

Table 2: The table presents sixty-four genes/proteins. Each protein is represented with a degree in PPI (Figure 3), disease count (out of 204), disease type count (out of 3), and pathway count (out of 31). Some of the proteins have other known virus target are also reported.

Gene	Degree	#Pathway	Disease category	#Disease count	Known target virus
ADAM17	10	2	Immune	1	
ALDOA	26	1	Cardiovascular	1	
AP3B1	17	1	Respiratory	2	
AREG	20	2	Respiratory, Cardiovascular, Immune	10	
ATM	29	6	Cardiovascular, Immune	8	
ATP2A2	10	1	Cardiovascular	11	
ATP6	19	5	Cardiovascular	1	Human SARS coronavirus, Bovine papillomavirus type 1, Human papillomavirus type 16
ATR	17	5	Respiratory	2	Human adenovirus 5
B2M	25	4	Cardiovascular, Immune	4	Hepatitis C virus genotype 1b (isolate Con1)
CANX	31	2	Cardiovascular	1	
CAPZB	34	1	Cardiovascular	1	
CAV1	22	2	Respiratory, Cardiovascular, Immune	17	Poliovirus type 1 (strain Sabin)
CD44	19	1	Immune	1	
COX2	9	3	Cardiovascular	1	
CRKL	11	5	Cardiovascular	4	
DDX58	10	6	Respiratory, Cardiovascular	2	
ENO1	13	1	Cardiovascular, Immune	2	
EPHA2	9	2	Cardiovascular	5	
FASN	9	1	Cardiovascular	10	
GAPDH	23	2	Cardiovascular	1	Hepatitis C virus genotype 1b (isolate Con1), Epstein-Barr virus (strain GD1)
GLA	16	1	Cardiovascular	5	
GNAQ	14	5	Cardiovascular	1	
GUSB	16	1	Immune	1	
HDAC2	12	5	Respiratory	2	Human herpesvirus 1 (strain 17), Human papillomavirus type 16, Human papillomavirus type 31
HLA-A	15	8	Immune	5	Epstein-Barr virus (strain GD1), Human papillomavirus type 16
HLA-C	14	8	Immune	7	
HMGCR	11	1	Immune	4	
HSPA1A	30	5	Cardiovascular	1	Epstein-Barr virus (strain GD1)
HSPA5	46	1	Respiratory, Cardiovascular	3	Epstein-Barr virus (strain GD1)
IFIH1	10	3	Respiratory, Cardiovascular, Immune	10	Sendai virus (strain Fushimi)
IGF2R	31	2	Respiratory	1	
ITCH	46	1	Immune	1	Epstein-Barr virus (strain B95-8)
ITGA6	10	3	Immune	1	
ITGB1	29	5	Cardiovascular	10	Hepatitis C virus genotype 1b (isolate Con1)
JAK2	22	2	Cardiovascular	6	
LDHA	14	1	Cardiovascular	4	
LDLR	20	2	Cardiovascular	4	
MET	18	4	Respiratory	1	
NDUFS2	20	3	Cardiovascular	3	
NF1	16	2	Cardiovascular	3	
NOTCH1	23	3	Cardiovascular	4	Hepatitis C virus genotype 1b (isolate Con1)
NOTCH2	11	2	Cardiovascular	1	
NOTCH3	15	3	Cardiovascular	2	
PARP1	14	1	Respiratory, Cardiovascular, Immune	17	Human herpesvirus 1 (strain 17)
PCNA	25	3	Immune	1	Human herpesvirus 1 (strain 17)
PDIA3	14	3	Cardiovascular	1	
PLAU	24	1	Respiratory, Cardiovascular, Immune	59	
PPP1CB	14	4	Cardiovascular	2	
PRKDC	15	1	Respiratory, Immune	3	Human herpesvirus 1 (strain 17)
PSMC5	34	1	Immune	7	Human adenovirus 5, Human adenovirus 12, Simian virus 40
PSMD6	24	1	Immune	2	
PTPN11	22	1	Cardiovascular	6	
RAB5A	40	3	Cardiovascular	1	
RAB7A	41	2	Cardiovascular	1	
RAB8A	40	3	Immune	1	
RBX1	58	4	Immune	5	
SERPINE1	16	4	Cardiovascular	8	
SLC9A1	12	2	Cardiovascular	7	
SORT1	14	1	Cardiovascular	3	
STAT6	11	1	Respiratory, Immune	4	
TGFB1	29	7	Respiratory, Cardiovascular, Immune	29	Hepatitis C virus genotype 1b (isolate Con1)
TGFBR1	17	9	Respiratory, Cardiovascular	6	
TGFBR2	16	8	Respiratory, Cardiovascular	13	
XPO1	25	2	Cardiovascular	2	

and diagnosis: Evolutionary origin to drug repurposing, Briefings in Bioinformatics (2020). URL: <https://doi.org/10.1093/bib/bbaa420>. doi:10.1093/bib/bbaa420.

[11] P. H. Guzzi, D. Mercatelli, C. Ceraolo, F. M. Giorgi, Master regulator analysis of the sars-cov-2/human

- interactome, *Journal of clinical medicine* 9 (2020) 982.
- [12] H.-H. Hoffmann, F. J. Sánchez-Rivera, W. M. Schneider, J. M. Luna, Y. M. Soto-Feliciano, A. W. Ashbrook, J. Le Pen, A. A. Leal, I. Ricardo-Lax, E. Michailidis, et al., Functional interrogation of a sars-cov-2 host protein interactome identifies unique and shared coronavirus host factors, *Cell Host & Microbe* (2020).
- [13] F. Messina, E. Giombini, C. Agrati, F. Vairo, T. A. Bartoli, S. Al Moghazi, M. Piacentini, F. Locatelli, G. Kobinger, M. Maeurer, et al., Covid-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of sars-cov-2 infection, *Journal of Translational Medicine* 18 (2020) 1–10.
- [14] J. Li, M. Guo, X. Tian, X. Wang, X. Yang, P. Wu, C. Liu, Z. Xiao, Y. Qu, Y. Yin, et al., Virus-host interactome and proteomic survey reveal potential virulence factors influencing sars-cov-2 pathogenesis, *Med* (2020).
- [15] M. Cannataro, P. H. Guzzi, P. Veltri, Impreco: Distributed prediction of protein complexes, *Future Generation Computer Systems* 26 (2010) 434–440.
- [16] G. Agapito, M. Cannataro, P. H. Guzzi, F. Marozzo, D. Talia, P. Trunfio, Cloud4snp: distributed analysis of snp microarray data on the cloud, in: *Proceedings of the International Conference on Bioinformatics, Computational Biology and Biomedical Informatics*, 2013, pp. 468–475.
- [17] D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M. White, M. J. O’Meara, V. V. Rezelj, J. Z. Guo, D. L. Swaney, et al., A sars-cov-2 protein interaction map reveals targets for drug repurposing, *Nature* (2020) 1–13.
- [18] Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, F. Cheng, Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2, *Cell discovery* 6 (2020) 1–18.
- [19] B. R. Beck, B. Shin, Y. Choi, S. Park, K. Kang, Predicting commercially available antiviral drugs that may act on the novel coronavirus (sars-cov-2) through a drug-target interaction deep learning model, *Computational and structural biotechnology journal* (2020).
- [20] V. Memišević, N. Zavaljevski, S. V. Rajagopala, K. Kwon, R. Pieper, D. DeShazer, J. Reifman, A. Wallqvist, Mining host-pathogen protein interactions to characterize burkholderia mallei infectivity mechanisms, *PLoS Comput Biol* 11 (2015) e1004088.
- [21] Q. Liang, J. Li, M. Guo, X. Tian, C. Liu, X. Wang, X. Yang, P. Wu, Z. Xiao, Y. Qu, et al., Virus-host interactome and proteomic survey of pmbcs from covid-19 patients reveal potential virulence factors influencing sars-cov-2 pathogenesis, *bioRxiv* (2020).
- [22] V. Thiel, K. A. Ivanov, A. Putics, T. Hertzog, B. Schelle, S. Bayer, B. Weißbrich, E. J. Snijder, H. Rabenau, H. W. Doerr, et al., Mechanisms and enzymes involved in sars coronavirus genome expression, *Journal of General Virology* 84 (2003) 2305–2315.
- [23] P. H. Guzzi, S. Roy, *Biological Network Analysis: Trends, Approaches, Graph Theory, and Algorithms*, Academic Press, 2020.
- [24] W. Li, L. Chen, W. He, W. Li, X. Qu, B. Liang, Q. Gao, C. Feng, X. Jia, Y. Lv, et al., Prioritizing disease candidate proteins in cardiomyopathy-specific protein-protein interaction networks based on “guilt by association” analysis, *PloS one* 8 (2013) e71191.
- [25] R. Ferrari, D. A. Kia, J. E. Tomkins, J. Hardy, N. W. Wood, R. C. Lovering, P. A. Lewis, C. Manzoni, Stratification of candidate genes for parkinson’s disease using weighted protein-protein interaction network analysis, *BMC genomics* 19 (2018) 1–8.
- [26] J. C. Galicia, P. H. Guzzi, F. M. Giorgi, A. A. Khan, Predicting the response of the dental pulp to sars-cov2 infection: a transcriptome-wide effect cross-analysis, *Genes & Immunity* 21 (2020) 360–363.
- [27] D. Lim, N.-K. Kim, H.-S. Park, S.-H. Lee, Y.-M. Cho, S. J. Oh, T.-H. Kim, H. Kim, Identification of candidate genes related to bovine marbling using protein-protein interaction networks, *International journal of biological sciences* 7 (2011) 992.
- [28] C. L. Tucker, J. F. Gera, P. Uetz, Towards an understanding of complex protein networks, *Trends in cell biology* 11 (2001) 102–106.

- [29] S. Thakur, M. Dhiman, G. Tell, A. K. Mantha, A review on protein–protein interaction network of *ape1/ref-1* and its associated biological functions, *Cell Biochemistry and Function* 33 (2015) 101–112.
- [30] A. Athanasios, V. Charalampos, T. Vasileios, et al., Protein-protein interaction (ppi) network: recent advances in drug discovery, *Current drug metabolism* 18 (2017) 5–10.
- [31] E. Chautard, N. Thierry-Mieg, S. Ricard-Blum, Interaction networks: from protein functions to drug discovery. a review, *Pathologie Biologie* 57 (2009) 324–333.
- [32] M. Nietzsche, R. Landgraf, T. Tohge, F. Börnke, A protein–protein interaction network linking the energy-sensor kinase *snrk1* to multiple signaling pathways in *arabidopsis thaliana*, *Current Plant Biology* 5 (2016) 36–44.
- [33] W. Lan, J. Wang, M. Li, W. Peng, F. Wu, Computational approaches for prioritizing candidate disease genes based on ppi networks, *Tsinghua Science and Technology* 20 (2015) 500–512.
- [34] N. Safari-Alighiarloo, M. Taghizadeh, M. Rezaei-Tavirani, B. Goliaei, A. A. Peyvandi, Protein-protein interaction networks (ppi) and complex diseases, *Gastroenterology and Hepatology from bed to bench* 7 (2014) 17.
- [35] Y. Wang, Y. Zhang, Q. Huang, C. Li, Integrated bioinformatics analysis reveals key candidate genes and pathways in breast cancer, *Molecular medicine reports* 17 (2018) 8091–8100.
- [36] H. Jeong, S. P. Mason, A.-L. Barabási, Z. N. Oltvai, Lethality and centrality in protein networks, *Nature* 411 (2001) 41–42.
- [37] K. Bösl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskienė, R. J. Cox, et al., Common nodes of virus–host interaction revealed through an integrated network analysis, *Frontiers in immunology* 10 (2019) 2186.
- [38] R. Albert, H. Jeong, A.-L. Barabási, Error and attack tolerance of complex networks, *nature* 406 (2000) 378–382.
- [39] V. Navratil, B. de Chassey, C. R. Combe, V. Lotteau, When the human viral infectome and disease networks collide: towards a systems biology platform for the aetiology of human diseases, *BMC systems biology* 5 (2011) 13.
- [40] R. R. Halehalli, H. A. Nagarajaram, Molecular principles of human virus protein–protein interactions, *Bioinformatics* 31 (2015) 1025–1033.
- [41] J. Xu, Y. Li, Discovering disease-genes by topological features in human protein–protein interaction network, *Bioinformatics* 22 (2006) 2800–2805.
- [42] A. Stukalov, V. Girault, V. Grass, V. Bergant, O. Karayel, C. Urban, D. A. Haas, Y. Huang, L. Oubraham, A. Wang, et al., Multi-level proteomics reveals host-perturbation strategies of sars-cov-2 and sars-cov, *Biorxiv* (2020).
- [43] C. Stark, B.-J. Breitkreutz, T. Reguly, L. Boucher, A. Breitkreutz, M. Tyers, Biogrid: a general repository for interaction datasets, *Nucleic acids research* 34 (2006) D535–D539.
- [44] D. Szklarczyk, A. Franceschini, M. Kuhn, M. Simonovic, A. Roth, P. Mínguez, T. Doerks, M. Stark, J. Müller, P. Bork, et al., The string database in 2011: functional interaction networks of proteins, globally integrated and scored, *Nucleic acids research* 39 (2010) D561–D568.
- [45] P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: a software environment for integrated models of biomolecular interaction networks, *Genome research* 13 (2003) 2498–2504.
- [46] P. Bonacich, Power and centrality: A family of measures, *American journal of sociology* 92 (1987) 1170–1182.
- [47] J.-D. J. Han, N. Bertin, T. Hao, D. S. Goldberg, G. F. Berriz, L. V. Zhang, D. Dupuy, A. J. Walhout, M. E. Cusick, F. P. Roth, et al., Evidence for dynamically organized modularity in the yeast protein–protein interaction network, *Nature* 430 (2004) 88–93.

- [48] J. Yoon, A. Blumer, K. Lee, An algorithm for modularity analysis of directed and weighted biological networks based on edge-betweenness centrality, *Bioinformatics* 22 (2006) 3106–3108.
- [49] M. E. Newman, A measure of betweenness centrality based on random walks, *Social networks* 27 (2005) 39–54.
- [50] G. Mao, N. Zhang, Analysis of average shortest-path length of scale-free network, *Journal of Applied Mathematics* 2013 (2013).
- [51] A.-L. Barabasi, Z. N. Oltvai, Network biology: understanding the cell’s functional organization, *Nature reviews genetics* 5 (2004) 101–113.
- [52] D. S. Goldberg, F. P. Roth, Assessing experimentally derived interactions in a small world, *Proceedings of the National Academy of Sciences* 100 (2003) 4372–4376.
- [53] S. Maslov, K. Sneppen, Specificity and stability in topology of protein networks, *Science* 296 (2002) 910–913.
- [54] M. Kanehisa, S. Goto, Kegg: kyoto encyclopedia of genes and genomes, *Nucleic acids research* 28 (2000) 27–30.
- [55] M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, et al., Gene ontology: tool for the unification of biology, *Nature genetics* 25 (2000) 25–29.
- [56] M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L. Jenkins, K. M. Jagodnik, A. Lachmann, et al., Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, *Nucleic acids research* 44 (2016) W90–W97.
- [57] K.-I. Goh, M. E. Cusick, D. Valle, B. Childs, M. Vidal, A.-L. Barabási, The human disease network, *Proceedings of the National Academy of Sciences* 104 (2007) 8685–8690.
- [58] W. T. C. C. Consortium, et al., Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, *Nature* 447 (2007) 661.
- [59] J. Piñero, J. M. Ramírez-Anguita, J. Saüch-Pitarch, F. Ronzano, E. Centeno, F. Sanz, L. I. Furlong, The disgenet knowledge platform for disease genomics: 2019 update, *Nucleic acids research* 48 (2020) D845–D855.
- [60] F. Seif, H. Aazami, M. Khoshmirsafa, M. Kamali, M. Mohsenzadegan, M. Pornour, D. Mansouri, Jak inhibition as a new treatment strategy for patients with covid-19, *International Archives of Allergy and Immunology* 181 (2020) 467–475.
- [61] H. Ganesan, V. Balasubramanian, M. Iyer, A. Venugopal, M. D. Subramaniam, S.-G. Cho, B. Vellingiri, mtor signalling pathway-a root cause for idiopathic autism?, *BMB reports* 52 (2019) 424.
- [62] W. Luo, Y.-X. Li, L.-J. Jiang, Q. Chen, T. Wang, D.-W. Ye, Targeting jak-stat signaling to control cytokine release syndrome in covid-19, *Trends in pharmacological sciences* (2020).
- [63] J. M. Grimes, K. V. Grimes, p38 mapk inhibition: A promising therapeutic approach for covid-19, *Journal of Molecular and Cellular Cardiology* (2020).
- [64] F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, et al., A new coronavirus associated with human respiratory disease in china, *Nature* 579 (2020) 265–269.
- [65] K. J. Clerkin, J. A. Fried, J. Raikhelkar, G. Sayer, J. M. Griffin, A. Masoumi, S. S. Jain, D. Burkhoff, D. Kumaraiah, L. Rabbani, et al., Covid-19 and cardiovascular disease, *Circulation* 141 (2020) 1648–1655.
- [66] P. C. Konturek, I. Harsch, M. Neurath, Y. Zopf, Covid-19-more than respiratory disease: a gastroenterologist’s perspective, *J Physiol Pharmacol* 71 (2020) 765–767.
- [67] G. Agapito, M. Simeoni, B. Calabrese, I. Caré, T. Lamprinoudi, P. H. Guzzi, A. Pujia, G. Fuiano, M. Canataro, Dietos: A dietary recommender system for chronic diseases monitoring and management, *Computer methods and programs in biomedicine* 153 (2018) 93–104.

- [68] C. Melenotte, A. Silvin, A.-G. Goubet, I. Lahmar, A. Dubuisson, A. Zumla, D. Raoult, M. Merad, B. Gachot, C. Hénon, et al., Immune responses during covid-19 infection, *OncoImmunology* 9 (2020) 1807836.
- [69] M. A. Chowdhury, N. Hossain, M. A. Kashem, M. A. Shahid, A. Alam, Immune response in covid-19: A review, *Journal of Infection and Public Health* (2020).
- [70] A. Chatr-Aryamontri, A. Ceol, D. Peluso, A. Nardozza, S. Panni, F. Sacco, M. Tinti, A. Smolyar, L. Castagnoli, M. Vidal, et al., Virusmint: a viral protein interaction database, *Nucleic acids research* 37 (2009) D669–D673.